(Q36707550)

15 August 2017

1 reference

title

Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors (English)

1 reference

15 August 2017

0 references

0 references

Coagulation factor VIII

0 references

0 references

1

Birgit M Reipert

1 reference

15 August 2017

3

Hans-Peter Schwarz

1 reference

15 August 2017

author name string

Pauline M W van Helden

series ordinal

2

1 reference

15 August 2017

Christina Hausl

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

British Journal of Haematology

15 August 2017

published in

1 reference

15 August 2017

volume

136

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

12-25

1 reference

Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Selection and fine-tuning of the autoimmune T-cell repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

In vivo instruction of suppressor commitment in naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immune tolerance induction: recombinant vs. human-derived product

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

The epitope recognized by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Peptide-based instruction of suppressor commitment in naïve T cells and dynamics of immunosuppression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

A Theory of Self-Nonself Discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

CD4+ T cells that enter the draining lymph nodes after antigen injection participate in the primary response and become central-memory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Generation of anergic and regulatory T cells following prolonged exposure to a harmless antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Achieving antigen-specific tolerance in diabetes: regulating specifically

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Cellular sites of immunologic unresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

T cell tolerance induced by therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Therapeutic idiotype vaccines in B lymphoproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immunologic unresponsiveness induced by protein antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Correlation between factor VIII genotype and inhibitor development in hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Development and function of CD25+CD4+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Naive and memory CD4+ T cell survival controlled by clonal abundance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Factor VIII inhibitors in mild and moderate-severity haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Current and future approaches to inhibitor management and aversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Effect of intermediate-purity factor VIII (FVIII) concentrate on lymphocyte proliferation and apoptosis: transforming growth factor-beta is a significant immunomodulatory component of FVIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF-beta as an immunomodulatory component in plasma-derived factor VIII concentrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Long-lived plasma cells and their contribution to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immunological tolerance in bone marrow-derived lymphocytes. 3. Tolerance induction in primed B cells by hapten conjugates of unrelated immunogenic or "nonimmunogenic" carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Catalytic activity of antibodies against factor VIII in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Dendritic cells: immune regulators in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Myeloma proteins as tumor-specific transplantation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Maintenance of serum antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

International immune tolerance registry, 1997 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immune tolerance induction in hemophilia A: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

MyD88 signaling controls autoimmune myocarditis induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Antigen-specific memory B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

In vitro tolerance induction of neonatal murine B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Environmental and genetic factors influencing inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Negative selection--clearing out the bad apples from the T-cell repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

CD20: a target antigen for immunotherapy of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immune activation: death, danger and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Clonal selection and learning in the antibody system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Central memory and effector memory T cell subsets: function, generation, and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Molecular identification of a danger signal that alerts the immune system to dying cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

The why and how of thymocyte negative selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

The control of immunity and tolerance by dendritic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

The genetic basis of inhibitor development in haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

The role of Toll-like receptors in immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Follicular B helper T cells in antibody responses and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Reprogramming the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

The enemy within: keeping self-reactive T cells at bay in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Regulatory CD4+ T cells and the control of autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06359.X

10.1111/J.1365-2141.2006.06359.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference